Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

Brian Brown, PhD, Director of the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai, has been elected ...

Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients more hope of ...

Scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into 'cold' tumors and flip on an immune ...

The data pertains to the company’s lead drug candidate, Reqorsa® Gene Therapy, for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC) resistant to Ras inhibitors. The study ...

The promotional effort from Ferring features bladder cancer survivors sharing the news of a new treatment option.

Researchers are conducting a groundbreaking trial that could revolutionize the way the body fights cancer, particularly for ...